(a) Approval 2 weeks ahead of pdufa. CBER pushing forward on their workload.
(b) Approved based on open label trial. (Downrampers always insisting we can't succeed without a double blind placebo controlled trial.)
(c) FDA actually did a press release on this one. Shows they find the continuing need for GVHD treatments to be compelling.
(d) And more evidence they find the need for GVHD treatments compelling: they had given this drug Orphan Drug Designation and Fast Track Designation.
(e) It will be a while before we are trying to treat chronic GVHD, and there is plenty of need for effective treatments, so I don't see this approval as concerning from a competitive standpoint. It is good for patients and reflects the importance of what we are trying to achieve.
.
Cell Therapy News/Articles, page-17994
-
- There are more pages in this discussion • 327 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.45 |
Change
-0.030(2.03%) |
Mkt cap ! $1.655B | |||
| Open | High | Low | Value | Volume |
| $1.48 | $1.51 | $1.43 | $6.613M | 4.498M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 2482 | $1.45 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.46 | 27045 | 2 |
View Market Depth
| Last trade - 16.10pm 18/10/2024 (20 minute delay) ? |
| MSB (ASX) Chart |